Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Bio-Fortune Ltd.
Beijing, Beijing Municipality, Chinatsbsino.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has developed a novel recombinant human serum albumin fusion protein drug for neutropenia. It has entered into a US market licensing agreement with a top global pharmaceutical company. Clinical progress includes one program through Phase I and another in late Phase II; additional programs are at earlier stages.[2][3][6]
- Therapeutic areas
- OncologyImmunologyInfectious DiseasesHematology
- Modalities
- Recombinant protein drugs (including fusion proteins)Gene-based therapeutics[1][6]
- Industry
- Biotech
02
Partnerships
Entered into a US market patent license agreement with an unnamed top ten global pharmaceutical company for its neutropenia treatment IP.[2]
Beyond the preview
Go deeper on Beijing Bio-Fortune Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Bio-Fortune Ltd..